Activation of Janus kinase 2 (JAK2) by chromosomal translocations or point mutations is a frequent event in haematological malignancies [1] [2] [3] [4] [5] [6] . JAK2 is a non-receptor tyrosine kinase that regulates several cellular processes by inducing cytoplasmic signalling cascades. Here we show that human JAK2 is present in the nucleus of haematopoietic cells and directly phosphorylates Tyr 41 (Y41) on histone H3. Heterochromatin protein 1a (HP1a), but not HP1b, specifically binds to this region of H3 through its chromo-shadow domain. Phosphorylation of H3Y41 by JAK2 prevents this binding. Inhibition of JAK2 activity in human leukaemic cells decreases both the expression of the haematopoietic oncogene lmo2 and the phosphorylation of H3Y41 at its promoter, while simultaneously increasing the binding of HP1a at the same site. These results identify a previously unrecognized nuclear role for JAK2 in the phosphorylation of H3Y41 and reveal a direct mechanistic link between two genes, jak2 and lmo2, involved in normal haematopoiesis and leukaemia [1] [2] [3] [4] [5] [6] [7] [8] [9] . JAK2 signalling is implicated in various biological processes, including cell cycle progression, apoptosis, mitotic recombination, genetic instability and alteration of heterochromatin [10] [11] [12] [13] . The most common somatic alteration of JAK2 is a gain-of-function mutation (JAK2 V617F) associated with human myeloproliferative diseases 1,2 . The diverse roles of JAK2 in normal and leukaemic haematopoiesis are believed to be mediated by cytoplasmic signalling pathways 1,2 . We found that JAK2 has a previously unrecognized nuclear pool in haematopoietic cells. Figure 1a and Supplementary Fig. 1 show JAK2 within the nuclei of three cell lines (HEL, UKE1 and SET2) harbouring JAK2 V617F 14 . However, JAK2 staining was also nuclear in K562 cells, which express wild-type JAK2. Nuclear JAK2 was also observed in primary cells, positive for the CD34 stem-cell antigen, obtained from a patient with JAK2 V617F-positive post-polycythaemic myelofibrosis. Transfection of JAK2 into a JAK2-null background, c-2A cells 15 , independently confirmed the nuclear localization of JAK2 and validated the specificity of the antibodies used in immunofluorescence ( Fig. 1b and Supplementary Fig. 2 ). Finally, subcellular fractionation experiments using HEL cells also demonstrated JAK2 in the nucleus (Fig. 1c) . Taken together, these results demonstrate that a significant proportion of JAK2 is present within the nuclei of haematopoietic cells, irrespective of JAK2 mutation status.
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To explore the role of JAK2 within the nucleus we investigated the possibility that histones could be a substrate. Among all core histones, we found that recombinant JAK2 specifically phosphorylated histone H3, a reaction inhibited by the JAK2 inhibitor TG101209 (ref. 16) (Fig. 2a and Supplementary Fig. 3 ). H3 contains three highly conserved tyrosine residues, one of which, H3Y41, is positioned at the amino terminus of the first helix of H3 (the aN1-helix) where DNA enters the nucleosome (Fig. 2b) . Given its accessible location, we reasoned that H3Y41 might be the JAK2 target; we therefore generated an antibody against phosphorylated H3Y41 (H3Y41ph), verified its specificity ( (Fig. 2c , lanes 1-6). H3Y41 phosphorylation was inhibited by TG101209 and by mutation of H3Y41 to phenylalanine (Fig. 2c, lanes 7-10) . Cellular JAK2, immunoprecipitated from HEL cells, also phosphorylated H3Y41 ( Supplementary Fig. 6 ).
To assess the phosphorylation of H3Y41 in vivo, chromatin preparations from six cell lines were probed with the H3Y41ph antibody. H3Y41 phosphorylation was more abundant in cell lines containing active JAK2 (SET2, HEL, UKE1 and K562) 14 , whereas H3Y41ph was significantly decreased in HL60 cells and c2A cells, which lack detectable JAK2 (refs 15, 17) (Fig. 2d) . Stimulation of K562 cells with leukaemia inhibitory factor (LIF) or platelet-derived growth factor-BB (PDGF-BB) resulted in activation of JAK2, as demonstrated by JAK2 phosphorylation, and produced a concomitant increase in H3Y41ph ( Fig. 2e and Supplementary Fig. 7a ). Moreover, stimulation of murine BaF3 cells with interleukin-3 (IL-3), a cytokine that signals by means of JAK2 in these cells, also increased H3Y41ph (Supplementary Fig. 7b ). Taken together, these data demonstrate that H3Y41ph is present in vivo and that cytokine signalling regulates its levels.
The presence of residual H3Y41ph in HL60 and JAK2-null c2A cells indicates that JAK2 is not the only kinase responsible for this modification. However, transfection of JAK2 into c2A cells demonstrated that it is one of the cellular kinases responsible for H3Y41ph in vivo (Fig. 2f) . To provide further evidence that JAK2 phosphorylates H3Y41 in vivo, we used two specific, chemically distinct JAK2 inhibitors, TG101209 and AT9283 (refs 16, 18) . Chromatin prepared from HEL cells grown in the presence of either JAK2 inhibitor contained significantly decreased H3Y41ph compared with non-treated cells (Supplementary Fig. 8b ). These changes were not a consequence of broad effects on cell cycle or apoptosis (Supplementary Fig. 8a ). Moreover, inhibition of JAK2 produced a rapid and sustained loss of H3Y41ph. The decrease in H3Y41ph occurred within 15 min, and by 1 h an 80% decrease was observed (Fig. 2g, h ). The rapidity of this response, together with the in vitro data, indicates that JAK2 directly phosphorylates H3Y41 in vivo. Core histones Purified H3 TG101209 rJAK2
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Anti-H3 LIF Time (min) Figure 2 | JAK2 phosphorylates H3Y41 in vitro and in vivo. a, In vitro kinase assay using [c- 32 P]ATP and recombinant JAK2 (rJAK2). b, H3 (blue) is shown in the nucleosome; the inset highlights H3Y41 at the amino terminus of the first helix. c, In vitro kinase assay followed by western blot analysis using the H3Y41ph antibody. d, H3Y41ph was measured in chromatin from the indicated cell lines by western blotting. e, After serum starvation, K562 cells were stimulated with LIF. H3Y41ph and phospho-JAK2 (anti-JAK2ph) were measured by western blot analyses of whole cell extracts. f, H3Y41ph was determined in chromatin from c2A cells, transfected with either wildtype JAK2, JAK2 V617F or empty vector. g, H3Y41ph was measured in chromatin from HEL cells grown in the presence of a specific JAK2 inhibitor (TG101209) or vehicle control (dimethylsulphoxide; DMSO). h, Quantification of western blot in g. Similar results were obtained with a second specific JAK2 inhibitor (AT9283; data not shown). The JAK pathway in Drosophila melanogaster has recently been implicated in the alteration of heterochromatin through the disruption of HP1 (ref. 13 ). We therefore investigated whether JAK2 signalling in a haematopoietic cell line (HEL) affected the association of HP1a or HP1b with chromatin. Figure 3a shows that there was a significant amount of soluble, non-chromatin-bound HP1a in permeabilized HEL nuclei, whereas HP1b was essentially bound to chromatin (Fig. 3a) . This observation raised the possibility that JAK2 signalling in HEL cells may weaken HP1a binding and/or stabilize the binding of HP1b.
Given that JAK2 directly phosphorylates H3Y41, we considered the possibility that H3 may contain an additional binding site for HP1a or HP1b near Y41. Figure 3b and Supplementary Fig. 9a, b show that HP1a bound specifically to an unmodified H3 peptide encompassing amino-acid residues 31-56. HP1a binding was markedly decreased when the peptide was phosphorylated at Y41. In contrast, HP1b bound neither the unmodified nor the modified peptide. The integrity of the H3Y41ph peptide was demonstrated by the fact that the H3Y41ph antibody bound only the phosphorylated peptide. Binding to the Y41 region of H3 was specifically mediated by the chromo-shadow domain (CSD) of HP1a, whereas its chromo domain has been shown to be responsible for its interaction with methylated H3K9 (H3K9me) (Fig. 3c ) 19, 20 . Indeed, H3K9me peptides added in trans neither stimulate nor inhibit the binding of HP1a to the Y41 region of H3 (Supplementary Fig. 9c ), but H3Y41 phosphorylation inhibited binding of the CSD to H3 (Fig. 3d) . Together these data demonstrate that the CSD of HP1a binds the Y41 region of H3 and that this binding is inhibited by H3Y41 phosphorylation.
To further characterize HP1a binding to H3 in a more physiological context, we performed immunofluorescence experiments with peptide competition. Figure 3e , f shows that peptides spanning H3 residues 31-56, and peptides containing trimethylated H3K9 (H3K9me3), displaced HP1a from nuclear heterochromatic speckles 19 . In contrast, a H3(31-56) peptide phosphorylated at Y41 (H3Y41ph) was unable to displace HP1a efficiently from heterochromatin. We next examined whether binding of HP1a is modulated by JAK2 signalling in vivo. Permeabilized nuclei were prepared from HEL cells cultured with or without JAK2 inhibitors. Inhibition of JAK2 increased the proportion of chromatin-bound HP1a within these nuclei ( Fig. 3g; compare lanes  2 and 3 with lane 1) . Whereas the level of H3Y41ph was decreased by inhibition of JAK2 (Fig. 2g and Supplementary Fig. 8b ), the level of H3K9me3 was unaltered, which is consistent with the concept that JAK2 signalling reduces HP1a binding by phosphorylating H3Y41.
To investigate the biological consequences of H3Y41 phosphorylation, we used expression arrays to identify JAK2-regulated genes in HEL cells (Fig. 4a and Supplementary Fig. 10a ). Of those genes whose messenger RNA levels were most decreased by inhibition of JAK2, several have previously been identified as transcriptional targets of ID1  IGFBP5  FLJ11795  PIM1  HSPA5  LOC317671  DARC  PIM2  HSPC111  TUBAL3  PLVAP  BCL2L1  GDF3  RAB3IL1  HMBS  SDF2L1  SLCO4A1  NME1  KCNH2  PCOLCE2  HBBP1  ISG20L1  PSKH2  LOC201164  LMO2  NOLA1  GPR56  C1ORF33  EGR1  FLJ43339  C1ORF186  RRS1  CCDC58  RGS19  XTP3TPA  TMC6  SLA2  KCNN4 the canonical JAK2-STAT5 pathway (reviewed in ref. 21 ). However, this approach also identified JAK2-regulated genes, including lmo2, that lacked a predicted STAT5-binding site as defined previously 22 . lmo2 is essential for normal haematopoietic development, has been implicated in leukaemogenesis 7, 9 and was in the top 0.5% of genes downregulated by inhibition of JAK2. The link between lmo2 expression and JAK2 inhibition has been noted previously 23 ; this was further confirmed by quantitative polymerase chain reaction with reverse transcription (RT-PCR) and with a second JAK2 inhibitor, AT9283 (Supplementary Fig. 10b, c) . Chromatin immunoprecipitation was then employed to investigate chromatin structure at lmo2 after inhibition of JAK2. Downregulation of lmo2 expression (corroborated by decreased levels of H3K4me3) was accompanied by decreased levels of H3Y41ph together with a reciprocal increase in the binding of HP1a, but not HP1b, at sites surrounding the lmo2 transcriptional start site (Fig. 4b, Supplementary Fig. 11 and data not shown). The promoter of B2M, a housekeeping gene encoding b 2 -microglobulin, and two sites upstream of the lmo2 promoter showed no changes in H3K4me3, H3Y41ph or HP1a (Fig. 4b and Supplementary Fig. 12 ). Collectively, these results demonstrate that JAK2 signalling results in H3Y41 phosphorylation and the exclusion of HP1a from the lmo2 promoter.
The data presented here demonstrate a novel nuclear function for JAK2 that is distinct from its established role as an initiator of cytoplasmic signalling cascades. In the nucleus, JAK2 mediates the phosphorylation of H3Y41 and excludes HP1a from a new binding site surrounding H3Y41. Given that H3Y41 lies within a region known to affect nucleosome remodelling 24 , phosphorylation of H3Y41 may regulate chromatin architecture around specific gene promoters.
The displacement of HP1a by JAK2 is likely to be tightly regulated in normal cells, whereas in malignancies driven by constitutive activation of JAK2, unregulated displacement of chromatin-bound HP1a may override its potential tumour suppressive functions (Fig. 4c) . HP1a is recognized to reduce mitotic recombination 25 , repress the transcription of heterochromatic genes 26 and preserve centromeric architecture, leading to the faithful segregation of sister chromatids 27 . Indeed, the phenotypic consequences of constitutive JAK2 activation in haematological malignancies (increased gene expression, mitotic recombination and genetic instability) 1, 2, 12 are consistent with the reversal of these HP1a functions. This suggestion is further supported by the fact that enforced overexpression of HP1 ameliorates the leukaemic phenotype of overactive JAK signalling in D. melanogaster 13 .
METHODS SUMMARY
Cell culture and isolation of peripheral blood stem cells were performed with standard methodology 12 . Immunofluorescence images were captured with an Olympus Fluoview FV1000 microscope, and cells were prepared and stained as described previously 12, 19 . Cell fractionation, immunoprecipitation, western blotting and kinase assays were performed with standard methodology 19 . Peptides (Supplementary Table 1 ) were synthesized by Almac Sciences and used for binding/competition assays as described previously 19 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Cell culture and transfection. HEL, SET2, UKE-1, HL60, K562 and BaF3 were grown in RPMI 1640 medium (Sigma-Aldrich), and c2A cells were grown in DMEM medium (Sigma-Aldrich 1 cells were washed once in 1 3 PBS before cytocentrifugation onto polylysine-coated microscope slides. c2A cells were grown on coverslips before washing in 1 3 PBS. Cells were fixed for 30 min in methanol at 220 uC. After stepwise incubation with a primary antibody, and then a secondary fluorescent antibody, cells were stained with Hoechst 33258 (Sigma-Aldrich) and mounted with Vectashield mounting medium (Vector laboratories). Confocal laser images were captured with an Olympus Fluoview FV1000 microscope equipped with a 403 oil-immersion lens. Image processing was performed with Photoshop (Adobe Systems). Cell fractionation, immunoprecipitation and immunoblotting. Cytoplasmic, nucleosolic and chromatin fractions were prepared from cells as described previously 28 . In brief, cells were washed twice in 1 3 PBS and once in buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol (DTT) and protease inhibitor cocktail). Cells were then pelleted and resuspended in buffer A with 0.1% (v/v) Nonidet P40 and incubated on ice for 10 min. The supernatant containing the cytoplasmic fraction was collected after centrifugation and the pellet was resuspended in an equal volume (relative to the cytoplasmic extract) of buffer B (20 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 300 mM NaCl, 0.5 mM DTT, 25% (v/v) glycerol, 0.25% Triton X-100, 0.2 mM EDTA and protease inhibitor cocktail). After centrifugation, the supernatant contains the nucleosolic fraction and the insoluble pellet is composed primarily of chromatin and associated proteins. Equal volumes of cytoplasmic and nucleosolic fractions were separated by SDS-PAGE, transferred to nitrocellulose and probed with relevant antibodies. For immunoprecipitation, cells were lysed in IPH (150 mM NaCl, 50 mM TrisHCl pH 8.0, 5 mM EDTA, 0.5% (v/v) Nonidet P40) on ice for 15 min and the supernatant was collected after centrifugation and used for immunoprecipitation. Sodium orthovanadate (1 mM) was added to all solutions when performing assays relating to the study of tyrosine phosphorylation. Extracted proteins were mixed with 2 3 Laemmli sample buffer, separated by SDS-PAGE, transferred to nitrocellulose or poly(vinylidene difluoride) (PVDF) membranes (Millipore) and stained with Ponceau S to ensure equal transfer. Membranes were then sequentially incubated with primary antibodies and secondary antibodies conjugated with horseradish peroxidase. Membranes were then incubated for enhanced chemiluminescence (ECL H ; GE Healthcare) and proteins were detected by exposure to X-ray film. Dot-blot assays were performed by spotting synthetic peptide onto pre-wetted PVDF membrane. The membrane was then sequentially probed with primary and secondary antibodies as above. If appropriate, the primary antibody incubation was performed in the presence of competitor peptides (1.0 mg ml 
